von Ameln Lovison Otávio, Zempulski Volpato Fabiana Caroline, Weber Lorenzo Gómez, Barth Afonso Luis, Simon Coitinho Adriana, Martins Andreza Francisco
Laboratório de Pesquisa em Resistência Bacteriana (LABRESIS), Hospital de Clínicas de Porto Alegre (HCPA), Centro de Pesquisa Experimental, Porto Alegre, Brazil.
Laboratório de Microbiologia e Saúde Única do Instituto de Ciências Básicas da Saúde (ICBS) da Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Front Cell Infect Microbiol. 2025 May 13;15:1531084. doi: 10.3389/fcimb.2025.1531084. eCollection 2025.
It is argued that commensal bacteria in the upper respiratory tract (URT) protect against pathogen colonization and infection, including respiratory viruses. Given that the microbiome can mediate immune modulation, a link between the URT microbiome (URTM) and COVID-19 susceptibility and severity is expected. This 16S metagenomics cross-sectional study assessed URTM composition, metabolic prediction, and association with laboratory biomarkers in non-COVID-19 pneumonia (NO-CoV), moderate (M-CoV), severe (S-CoV) COVID-19 patients, as well as COVID-19-negative, asymptomatic (NC) patients. The S-CoV group exhibited reduced URTM diversity, primarily due to a decreased abundance of eubiotic taxa. Some of these taxa (e.g., sp., sp.) were also associated with inflammatory biomarkers. Multiple metabolic pathways (e.g., short-chain fatty acids, vitamin B12) linked to immune response, antiviral activity, and host susceptibility showed decreased abundance in S-CoV. These pathways could suggest potential alternatives for the therapeutic arsenal against COVID-19, providing reassurance about the progress in understanding and treating this disease.
有人认为，上呼吸道（URT）中的共生细菌可预防病原体定植和感染，包括呼吸道病毒。鉴于微生物群可介导免疫调节，预计URT微生物群（URTM）与COVID-19易感性和严重程度之间存在联系。这项16S宏基因组学横断面研究评估了非COVID-19肺炎（NO-CoV）、中度（M-CoV）、重度（S-CoV）COVID-19患者以及COVID-19阴性无症状（NC）患者的URTM组成、代谢预测以及与实验室生物标志物的关联。S-CoV组的URTM多样性降低，主要是由于有益生物类群的丰度降低。其中一些类群（如 属、 属）也与炎症生物标志物有关。与免疫反应、抗病毒活性和宿主易感性相关的多种代谢途径（如短链脂肪酸、维生素B12）在S-CoV组中的丰度降低。这些途径可能为对抗COVID-19的治疗手段提供潜在的替代方案，为理解和治疗这种疾病的进展提供保障。
